Moderna's Cancer Vaccine Triumph: What This Means for Investors
Moderna's stock surged 176.97% after successful Phase 3 trial results for its cancer vaccine, signaling potential market shifts.
Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger
Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million private placement, focusing on oncology.
TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz
TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by its drug BRIUMVI's FDA approval.
Werewolf Therapeutics and Ambros Therapeutics Join Forces: Implications for Oncology Investors
A strategic merger between Werewolf and Ambros Therapeutics aims to enhance oncology therapeutics, raising $150 million in the process.
Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology
Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and investor interest.
Ultragenyx's GENGLYCOS Approval: A Game Changer for Rare Disease Therapies
Ultragenyx's recent FDA approval for GENGLYCOS signals a significant shift in rare disease treatments.
Ultragenyx Pharma's Surge: FDA Approval for GENGLYCOS and Its Market Implications
Ultragenyx Pharma's shares jumped ~14% following FDA approval for GENGLYCOS, highlighting its potential in the gene therapy market.
Moderna's Landmark Phase 3 Win: What It Means for MRNA and the Biotech Sector
Moderna's recent Phase 3 trial success has sent shockwaves through the biotech sector, propelling its stock and igniting investor interest.
Merck's Breakthrough: Analysts React to Positive Drug Trial News
Analysts are optimistic about Merck's future after a 7.4% surge in shares following positive trial results.
Amylyx Pharmaceuticals' 55% Surge: A Turning Point for Avexitide and Biotech Investors
Amylyx Pharmaceuticals saw a 55% surge following positive results from its avexitide trial, signaling strong investor confidence.
Moderna's Historic Phase 3 Cancer Vaccine Triumph: What Investors Need to Know
Moderna's stock saw a significant surge following its Phase 3 cancer vaccine success, indicating a pivotal moment for investors.
Curaleaf's Hostile Takeover Bid: A Game Changer for the Cannabis Industry
Curaleaf's $4/share bid for Aurora Cannabis could reshape the cannabis landscape, creating ripples across the US and Canadian markets.